May 21, 2019 (GLOBE NEWSWIRE) -- Wayland Group Corp. (CSE:WAYL) (FRANKFURT: 75M) (OTCQB:MRRCF) (“Wayland” or the “Company”) today announced that its joint venture DEMECAN GmbH (“DEMECAN”), of which it holds 50% with an option to increase to 60% has been awarded three lots of domestic cannabis production in Germany by the Federal Institute for Drugs and Medical Devices (“BfArM”), after the withdrawal of a competitor’s complaint following an oral court hearing.
Read more
Wayland Group Confirms “BfARM” award for German Cannabis production
